Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
Chronic Lymphocytic Leukemia
DRUG: Alemtuzumab (MabCampath)
Efficacy related variables are patient's condition, physician's assessment of efficacy and tolerability, information whether application could be completed, clinical and laboratory findings. Safety Variables., After first cycle of treatment, e.g. 12 weeks, then after 9 months
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.